DT&CRO Co Ltd
DT&CRO's capital structure shows a debt-to-equity ratio of 1.44, indicating a leveraged position relative to equity. The company's liquidity is constrained, with a current ratio of 0.52, suggesting short-term obligations may exceed current assets. Free cash flow is negative at -8.4 billion KRW, and operating cash flow is also negative at -2.3 billion KRW, reflecting ongoing cash outflows from operations. Profitability metrics are negative, with a return on equity of -11.07% and a return on assets of -3.07%, both significantly below industry norms for contract research organizations. The company reported a net loss of 2.8 billion KRW and an operating loss of 5.7 billion KRW, indicating a challenging operating environment. Revenue is concentrated in a single business segment focused on contract research, with no disclosed geographic diversification in the financial snapshot. This lack of segment or geographic diversification increases exposure to sector-specific risks. Growth trajectory is uncertain, with no forward-looking revenue guidance provided in the financial snapshot. Historical performance shows declining profitability, with a net loss in the latest reporting period. The company's capital expenditure of -11.9 billion KRW suggests investment in infrastructure, but this has not yet translated into positive cash flow or profitability. Risk factors include liquidity constraints and a leveraged capital structure. The company has a medium liquidity risk rating, and its net cash position is negative after subtracting total debt. Dilution risk is low, with no near-term pressure from share issuance or convertible debt. Recent filings and transcripts are not included in the input data, so no specific events can be cited for the latest period.
Business. DT&CRO Co Ltd provides non-clinical and clinical trial services in pharmaceuticals, medical devices, food, chemicals, and cosmetics.
Classification. DT&CRO is classified in the Healthcare Facilities & Services industry under the Healthcare Services & Equipment business sector with 92% confidence.
- DT&CRO operates in a specialized healthcare services sector with high capital intensity.
- The company is currently unprofitable, with negative returns on equity and assets.
- Liquidity is a concern, with a current ratio below 1 and negative operating cash flow.
- Growth is uncertain without clear revenue guidance or profitability improvement.
- The business is concentrated in a single segment, increasing sector-specific risk.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.